The U.S. SEC filed insider trading charges against Ruimin Xie, the former director of analytical development at Bellus Health Inc., for allegedly receiving ill-gotten gains of $59,408.42 by acting on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results